Presbyopia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations and Other Developments

  • ID: 4470335
  • Report
  • Region: Global
  • 77 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Allergan Plc
  • Novartis AG
  • MORE

The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a customary working distance without experiencing visual symptoms. The disease can result from the gradual decrease in the amplitude of accommodation.

Insights on Pipeline Segments:

Various pharmaceutical companies such as Novartis AG, Allergan Plc., Janssen Global Services LLC, and Acucela Inc. are engaged in the development drug candidates for the treatment of presbyopia.

Positive clinical results of presbyopia drug candidates

Various pharmaceutical companies are developing drug candidates for the treatment of presbyopia, which have shown positive results in different stages of development. For instance, UNR844 showed a statistically significant difference to placebo in distant corrected near vision at all time points measured (from day 8) in the Phase I/II, placebo-controlled, proof-of-concept study carried out in 50 patients daily for 90 days with topical UNR844 and in 25 patients with placebo. At day 90, 82% of participants treated with UNR844 had 20/40 near vision (or 0.30 LogMAR) versus 48% in the placebo group. Near vision of 20/40 allows the majority of near vision tasks in most people.

Novel delivery systems and patented technologies for Presbyopia

Various pharmaceutical companies are involved in manufacturing drugs for the treatment of presbyopia. In January 2017, Alcon, the eye care division of Novartis AG, launched AcrySof IQ PanOptix Toric intraocular lens for presbyopia. The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant achievement in presbyopia treatment. Most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of presbyopia.

Some of the key players developing Novartis AG, Allergan Plc, and ORASIS Pharmaceuticals Ltd.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acucela Inc
  • Allergan Plc
  • Novartis AG
  • MORE
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 by industry participant
2.2.1.2 by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.1.1 Theories of Accommodation
4.1.1.1 The Helmholtz theory of accommodation
4.1.1.2 The Schachar theory of accommodation
4.1.1.3 The Coleman theory of accommodation
4.2 Epidemiology
4.3 Classification of Presbyopia
4.4 Sign and Symptoms
4.5 Etiology of Presbyopia
4.6 Prognosis and Follow-up
4.7 Treatment
4.8 Key Drivers
4.8.1 Driver 1
4.8.2 Driver 2
4.9 Key Barriers
4.9.1 Barrier 1
4.9.2 Barrier 2
4.1 Presbyopia Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company

5. Presbyopia Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase II/III
5.1.1 X
5.1.1.1 Clinical trials
5.1.1.2 Clinical trial results
5.2 Phase II
5.2.1 Oxymetazoline Hydrochloride + Pilocarpine Hydrochloride
5.2.1.1 Clinical trials
5.2.1.2 Clinical trial results
5.2.1.3 Strategic developments
5.2.2 X
5.2.2.1 Clinical trials
5.2.2.2 Clinical trial results
5.2.3 X
5.2.3.1 Clinical trials
5.2.3.2 Clinical trial results
5.2.4 XXX
5.2.4.1 Clinical trials
5.2.4.2 Clinical trial results
5.2.4.3 Patents
5.3 Phase I
5.3.1 EV06 Ophthalmic Solution
5.3.1.1 Clinical trials
5.3.1.2 Clinical trial results
5.3.1.3 Strategic developments
5.4 Pre-Clinical
5.4.1 VP1-001
5.4.1.1 Strategic developments
5.4.2 X
5.5 Discovery
5.5.1 X
5.5.1.1 Strategic developments

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for Presbyopia Therapeutics Pipeline
7.2 SWOT Analysis of Presbyopia Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Allergan Plc.
8.1.1 Business Overview
8.1.2 Product and Service Offerings
8.2 Novartis AG
8.2.1 Business Overview
8.2.2 Product and Service Offerings
8.3 X
8.3.1 Business Overview
8.3.2 Product and Service Offerings
8.4 X
8.4.1 Business Overview
8.4.2 Product and Service Offerings
8.5 X
8.5.1 Business Overview
8.5.2 Product and Service Offerings
8.6 X
8.6.1 Business Overview
8.6.2 Product and Service Offerings
8.7 X
8.7.1 Business Overview
8.7.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations
9.1 Related Reports

List of Tables
Table 1: Pipeline Analysis of Presbyopia Therapeutics, by Company (2018)
Table 2: Description of X
Table 3: Clinical Trials of X
Table 4: Description of (Oxymetazoline Hydrochloride + Pilocarpine Hydrochloride)
Table 5: Clinical Trials of (Oxymetazoline Hydrochloride + Pilocarpine Hydrochloride)
Table 6: Description of X
Table 7: Clinical Trials of X
Table 8: Description of X
Table 9: Clinical Trials of X
Table 10: Description of X
Table 11: Clinical Trials of X
Table 12: Description of Ev06 Ophthalmic Solution
Table 13: Clinical Trials of Ev06 Ophthalmic Solution
Table 14: Description of Vp1-001
Table 15: Description of X
Table 16: Description of X
Table 17: Allergan Plc. - at a Glance
Table 18: Novartis Ag - at a Glance
Table 19: X - at a Glance
Table 20: X - at a Glance
Table 21: X - at a Glance
Table 22: X - at a Glance
Table 23: X - at a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Split of Primary And Secondary Research
Fig 3: Breakdown of Primary Research Respondents, by Industry Participant
Fig 4: Breakdown of Primary Research Respondents, by Company Type
Fig 5: Presbyopia In Human Eye
Fig 6: Application of The Helmholtz Theory of Accommodation In Presbyopia
Fig 7: Application of The Schachar Theory of Accommodation In Presbyopia
Fig 8: Application of The Coleman Theory of Accommodation In Presbyopia
Fig 9: Presbyopic Surgical Methods
Fig 10: Presbyopia Drug Candidates Under Development (2018)
Fig 11: Presbyopia Pipeline Split, by Molecule Type (2018)
Fig 12: Breakdown of Clinical Trials, by Region
Fig 13: Breakdown of Clinical Trials, by Trial Status
Fig 14: Key Players Benchmarking
Fig 15: Swot Analysis
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acucela Inc
  • Allergan Plc
  • Janssen Global Services LLC
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll